NeoGenomics (NEO) CFO Abhishek Jain granted options and RSUs

Rhea-AI Filing Summary

NeoGenomics Inc. Chief Financial Officer Abhishek Jain reported his initial equity holdings. On January 13, 2026, he was granted 183,578 stock options and 110,088 restricted stock units, which vest ratably over the first three anniversaries of the grant date. Once vested, the underlying common shares are not subject to expiration.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Jain Abhishek

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Restricted Stock Unit	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 183,578 shares (Direct); Restricted Stock Unit — 110,088 shares (Direct)

Footnotes (1)

1. On January 13, 2026, Mr. Jain was granted 183,578 stock options. The options vest ratably over the first three anniversary dates of the grant date. On January 13, 2026, Mr. Jain was granted 110,088 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jain Abhishek

(Last) (First) (Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS FL 33912

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/02/2026

3. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	01/13/2036	Common Stock	183,578	$13.74	D
Restricted Stock Unit	(2)	(3)	Common Stock	110,088	$0	D

Explanation of Responses:

1. On January 13, 2026, Mr. Jain was granted 183,578 stock options. The options vest ratably over the first three anniversary dates of the grant date.

2. On January 13, 2026, Mr. Jain was granted 110,088 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

3. Once vested, the shares of common stock are not subject to expiration.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did NeoGenomics (NEO) CFO Abhishek Jain report on his Form 3?

Abhishek Jain reported being granted 183,578 stock options and 110,088 restricted stock units. Both awards were granted on January 13, 2026 and represent his initial reported equity position as Chief Financial Officer of NeoGenomics Inc., subject to time-based vesting conditions.

When do Abhishek Jain’s NeoGenomics (NEO) stock options and RSUs vest?

Both the 183,578 stock options and 110,088 restricted stock units vest ratably over the first three anniversaries of the January 13, 2026 grant date. This means portions of each award are scheduled to vest annually over a three-year period.

Are the NeoGenomics (NEO) shares from Abhishek Jain’s awards subject to expiration once vested?

According to the disclosure, once the awards vest, the resulting shares of NeoGenomics common stock are not subject to expiration. This applies to the shares delivered from the vested stock options and restricted stock units after they have fully vested.

What type of securities are included in Abhishek Jain’s NeoGenomics (NEO) Form 3 filing?

The filing lists two types of securities: a stock option described as a right to buy NeoGenomics common stock, and restricted stock units. Both are equity-based compensation instruments commonly used to align executive incentives with shareholder interests.

Does the NeoGenomics (NEO) Form 3 show Abhishek Jain buying or selling stock in the market?

The Form 3 reflects equity awards granted to Abhishek Jain rather than open-market purchases or sales. It records his initial beneficial ownership in the form of stock options and restricted stock units granted on January 13, 2026 with multi-year vesting terms.